New assessments from GARFIELD-AF (Global Anticoagulant Registry in the Field – Atrial Fibrillation) are being presented between June 20 and 25 at the XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Toronto, Canada. The two GARFIELD presentations will share real-life data concerning prevention of stroke from almost 17,200 patients in order to provide physicians with further knowledge on how patient quality of vitamin K antagonist control and risk profiles are linked with higher mortality rates and stroke in those with recently diagnosed AF.
The oral presentations include: Risk profiles and 1-year outcomes of patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF (Abstract OR119), which was held on Monday 22 June, 2015. This study covered the incidence of stroke, death, systemic embolism and major bleeding one year after a diagnosis, evaluated by patients’ baseline characteristics and antithrombotic therapy given at the time of diagnosis.
Quality of vitamin K antagonist control and 1-year outcomes: A global perspective from the GARFIELD-AF Registry (Abstract OR096) was also held on Monday, a study which evaluated time in therapeutic range (TTR) and optimal international normalized ratio in individuals suffering with newly diagnosed non-valvular AF concerning care settings, demographics and 1-year outcomes.
The GARFIELD-AF Registry is being used to emphasize all of the issues concerning stroke prevention in AF, and will assist the advancement of strategies that might improve patients’ outcomes around the world. Baseline data includes information on 31,666 patients, revealing that the manner in which many newly diagnosed patients are managed is not consistent. Researcher argue that patients are inappropriately being prescribed anticoagulants or are under-treated with anticoagulants, even with the higher availability of non-vitamin K antagonist oral anticoagulants (NOACs).
GARFIELD-AF is a multi center, observational and international prospective assessment of patients with newly diagnosed AF and will prospectively follow 57,000 patients from 35 countries and 1,000 centers worldwide. It is an independent academic research initiative, guided by the international steering committee under the auspices of the Thrombosis Research Institute (TRI), London, UK. More than 40,000 newly diagnosed AF patients have been recruited which make this one of the biggest observational studies in this specific therapeutic area.
Read More Recent News
After 20 years of research, a study recently published in Nature Genetics has revealed the genetic causes of a rare and curious syndrome that is similar to hypertension and accompanied by patients with short fingers (brachydactyly type E). There are only 6 unrelated families in the world who have this syndrome; they are from the United States, France, Turkey, South America, and two from Canada. All these individuals share a mutation in a tiny region of phosphodiesterase 3A (PDE3A), which modifies the resistance of blood vessels and the mechanism through which blood pressure is regulated. The researchers believe that the rare syndrome could provide insight into how and why people develop hypertension and suffer heart failure.
